<DOC>
	<DOCNO>NCT00988728</DOCNO>
	<brief_summary>The purpose study ass whether SCH 900435 ( Org 25935 ) 16 mg twice daily effective placebo treatment patient schizophrenia , use olanzapine 15 mg daily active control .</brief_summary>
	<brief_title>Efficacy &amp; Safety SCH 900435 Schizophrenia ( Study P06079 ) ( WITHDRAWN )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subjects eligible participate : present substantial recent exacerbation schizophrenia respond positively treatment antipsychotic clozapine past without adequate treatment symptom , willing capable stop concurrent medication , appear inadequate treat condition , prior participation Schizoaffective disorder ; single episode schizophrenia partial remission concomitant use antidepressant , moodstabilizers ( include anticonvulsant ) longacting sedative substance abuse dependence ( exclude nicotine caffeine ) uncompensated medical illness ( include clinically relevant eye disorder )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>